Efficacia e sicurezza di diversi regimi antitrombotici del trial AUGUSTS in base ai punteggi di rischio HAS-BLED e CHA₂DS₂- VASc

Background

- Approximately 20%-30% of patients with atrial fibrillation (AF) have concomitant coronary artery disease
- Patients with AF who have an acute coronary syndrome (ACS) and/or undergo percutaneous coronary intervention (PCI) have an indication for both anticoagulation and dual antiplatelet therapy (DAPT) with aspirin and a P2Y₁₂ inhibitor, but the risk of bleeding complications with triple antithrombotic ttherapy can be unacceptably high.
- Recent clinical trials have demonstrated that double antithrombotic therapy with a P2Y₁₂ inhibitor plus a direct oral anticoagulant (DOAC) provides an optimal balance in protecting against ischemic events while avoiding major bleeding in many patients; however, there may be subgroups of patients with higher or lower bleeding or thromboembolic risk that benefit from more potent antithrombotic therapy.

Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention



Ralf E. Harskamp, MD, PHD,^a Alexander C. Fanaroff, MD, MHS,^b Renato D. Lopes, MD, PHD,^c Daniel M. Wojdyla, MS,^c Shaun G. Goodman, MD, MSc,^{d,e} Laine E. Thomas, PHD,^c Ronald Aronson, MD,^f Stephan Windecker, MD,^g Roxana Mehran, MD,^h Christopher B. Granger, MD,^c John H. Alexander, MD, MHS^c

Objective

 The authors assessed the safety and efficacy of antithrombotic regimens according to HAS-BLED and CHA2DS2-VASc scores in AUGUSTUS (The Open-Label, 2 x 2 Factorial, Randomized, Controlled Clinical Trial to Evaluate the Safety of Apixaban vs.
Vitamin K Antagonist and Aspirin vs. Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention).

Methods

- In AUGUSTUS, 4614 patients were randomized in a 2-by-2 factorial design to open-label apixaban or VKA and blinded aspirin or placebo.
- The primary endpoint was major or clinically relevant nonmajor bleeding over 6 months of follow-up.
- Cox proportional hazard models were used to assess treatment effects by baseline HAS-BLED (≤2 vs ≥3) and CHA₂DS₂-VASc (≤2 vs ≥3) scores.
- Nonprespecified, post hoc analysis

Patient Characteristics Stratified by Stroke and Bleeding Risk

J Am Coll Cardiol 2022;79:417–427

	Overall	CHA ₂	A2DS2-VASc		HAS-BLED	
	(N = 4,386)	≤ 2 (n = 803)	≥3 (n = 3,583)	≤ 2 (n = 1,455)	≥3 (n = 2,931)	
Age, y	71 (64, 77)	62 (57, 65)	73 (67, 78)	63 (59, 70)	73 (68, 79)	
Women	1,289/4,386 (29.4)	32/803 (4.0)	1,257/3,583 (35.1)	330/1,455 (22.7)	959/2,931 (32.7)	
Race						
White	4,018/4,339 (92.6)	704/787 (89.5)	3,314/3,552 (93.3)	1,324/1,439 (92.0)	2,694/2,900 (92.9)	
Black	56/4,339 (1.3)	3/787 (0.4)	53/3,552 (1.5)	19/1,439 (1.3)	37/2,900 (1.3)	
Asian	102/4,339 (2.4)	30/787 (3.8)	72/3,552 (2.0)	42/1,439 (2.9)	60/2,900 (2.1)	
Native American	13/4,339 (0.3)	5/787 (0.6)	8/3,552 (0.2)	3/1,439 (0.2)	10/2,900 (0.3)	
Other	150/4,339 (3.5)	45/787 (5.7)	105/3,552 (3.0)	51/1,439 (3.5)	99/2,900 (3.4)	
Serum creatinine						
<1.5 mg/dL	3,946/4,311 (91.5)	743/790 (94.1)	3,203/3,521 (91.0)	1,351/1,430 (94.5)	2,595/2,881 (90.1)	
≥1.5 mg/dL	365/4,311 (8.5)	47/790 (5.9)	318/3,521 (9.0)	79/1,430 (5.5)	286/2,881 (9.9)	
Prior bleeding	47/4,368 (1.1)	3/799 (0.4)	44/3,569 (1.2)	4/1,451 (0.3)	43/2,917 (1.5)	
Hypertension	3,984/4,386 (90.8)	621/803 (77.3)	3363/3,583 (93.9)	1,118/1,455 (76.8)	2,866/2,931 (97.8)	
Heart failure	1,949/4,386 (44.4)	188/803 (23.4)	1,761/3,583 (49.1)	654/1,455 (44.9)	1,295/2,931 (44.2)	
Diabetes mellitus	1,633/4,386 (37.2)	104/803 (13.0)	1,529/3,583 (42.7)	476/1,455 (32.7)	1,157/2,931 (39.5)	
Stroke, TIA, or thromboembolism	619/4,386 (14.1)	0/803 (0.0)	619/3,583 (17.3)	78/1,455 (5.4)	541/2,931 (18.5)	
HAS-BLED	3 (2, 3)	2 (2, 3)	3 (3, 4)	_	_	
CHA ₂ DS ₂ -VASc	4 (3, 5)	-	-	3 (2,4)	4 (3, 5)	

Patient Management Stratified by Stroke and Bleeding Risk

	Overall	CHA₂I	DS ₂ -VASc	HAS	-BLED
	(N = 4,386)	≤ 2 (n = 803)	≥ 3 (n = 3,583)	≤ 2 (n = 1,455)	≥ 3 (n = 2,931)
Qualifying index event					
Acute coronary syndrome and PCI	1,617/4,373 (37.0)	326/800 (40.8)	1,291/3,573 (36.1)	521/1,448 (36.0)	1,096/2,925 (37.5)
Medically managed acute coronary syndrome	1,070/4,373 (24.5)	163/800 (20.4)	907/3,573 (25.4)	400/1,448 (27.6)	670/2,925 (22.9)
Elective PCI	1,686/4,373 (38.6)	311/800 (38.9)	1,375/3,573 (38.5)	527/1,448 (36.4)	1,159/2,925 (39.6)
Number of days from ACS or PCI to randomization	6 (3, 10)	5 (2, 10)	6 (3, 10)	6 (3, 10)	6 (3, 10)
Low-dose apixaban (2.5 mg twice daily) in patients randomized to apixaban	216/2,178 (9.9)	25/414 (6.0)	191/1,764 (10.8)	54/722 (7.5)	162/1,456 (11.1)
Concomitant P2Y ₁₂ inhibitor at randomization					
Clopidogrel	3,970/4,281 (92.7)	708/785 (90.2)	3,262/3,496 (93.3)	1,298/1,403 (92.5)	2,672/2,878 (92.8)
Prasugrel	46/4,281 (1.1)	19/785 (2.4)	27/3,496 (0.8)	23/1,403 (1.6)	23/2,878 (0.8)
Ticagrelor	265/4,281 (6.2)	58/785 (7.4)	207/3,496 (5.9)	82/1,403 (5.8)	183/2,878 (6.4)
Previous use of oral anticoagulant	2,171/4,386 (49.5)	345/803 (43.0)	1,826/3,583 (51.0)	681/1,455 (46.8)	1,490/2,931 (50.8)
Time in therapeutic range (VKA only)	58.5 (33.6-80.8)	58.0 (34.5-79.2)	58.8 (33.5-81.2)	58.1 (34.2-79.2)	58.9 (33.3-81.7)
Discontinued anticoagulant prematurely	565/4,325 (13.1)	78/793 (9.8)	487/3,532 (13.8)	155/1,438 (10.8)	410/2,887 (14.2)
Discontinued antiplatelet prematurely	674/4,333 (15.6)	85/794 (10.7)	589/3,539 (16.6)	167/1,441 (11.6)	507/2,892 (17.5)

Treatment Effect of Antithrombotic Regimens on Bleeding Events

	Number (Rate) of Apixaban	Events at 6 Mo VKA	onths HR	(95% CI)	Interaction <i>P</i> Value
ISTH major bleeding					0.722
≤2	16 (2.3%)	27 (4.0%)	0.57 (0.30-1.05)		
≥3	50 (3.7%)	72 (5.6%)	0.64 (0.45-0.92)	11	
ISTH major or CRNM ble	eeding				0.230
≤2	61 (8.8%)	98 (14.4%)	0.57 (0.41-0.78)		
≥3	165 (12.1%)	214 (16.3%)	0.72 (0.59-0.88)		

в

А

ISTH major bleeding						
						0.205
≤2 24	(3.6%)	21 (3.0%)	1.20 (0.67-2.16))	(
≥3 78	3 (5.9%)	43 (3.4%)	1.88 (1.30-2.73))		
ISTH major or CRNM bleeding						0.881
≤2 102	2 (15.1%)	59 (8.4%)	1.86 (1.36-2.56))		
≥3 239	9 (17.8%)	137 (10.4%)	1.81 (1.47-2.23)			

- The treatment effect of (A) apixaban vs VKA and (B) aspirin vs placebo on ISTH major and major or CRNM bleeding by HAS-BLED category.
- There was no treatment effect interaction by baseline bleeding risk for the comparison of apixaban vs VKA or placebo vs aspirin; patients randomized to apixaban and placebo had a lower risk of major and CRNM bleeding regardless of baseline bleeding risk.

Event/Risk Score	KM% at 6 Mor Apixaban	nths [Events] VKA	HR (95% CI) Apixaban vs VKA	
ISTH Major or CRNM Ble	eding			
HAS-BLED				
0 (N = 2)	0.0 [0]			
1 (N = 258)	7.7 [10]	14.4 [17]	0.53 (0.24-1.16)	
2 (N = 1,195)	9.1 [51]	14.4 [81]	0.58 (0.41-0.82)	
3 (N = 1,975)	10.9 [101]	17.0 [152]	0.61 (0.48-0.79)	
4 (N = 761)	15.6 [55]	13.3 [45]	1.17 (0.79-1.73)	
5 (N = 169)	12.1 [9]	24.9 [17]	0.48 (0.21-1.08)	
6 (N = 24)	0.0 [0]	0.0 [0]		
7 (N = 2)	0.0 [0]			
Death or Ischemic Event	s			
CHA2DS2-VASc				
1 (N = 168)	1.2 [1]	2.4 [2]		
2 (N = 635)	3.4 [11]	3.7 [11]	0.90 (0.39-2.07)	
3 (N = 997)	4.7 [23]	6.6 [33]	0.74 (0.44-1.25)	
4 (N = 1,083)	8.0 [40]	6.1 [33]	1.25 (0.79-1.99)	
5 (N = 805)	7.6 [30]	6.7 [25]	1.14 (0.67-1.94)	
6 (N = 428)	9.8 [20]	11.0 [24]	0.86 (0.48-1.54)	
7 (N = 197)	10.0 [10]	12.4 [11]	0.80 (0.35-1.84)	
8 (N = 63)	14.3 [4]	12.4 [4]	1.20 (0.30-4.80)	
9 (N = 10)	0.0 [0]	16.7 [1]		
				0.25 0.5 1 2 4

Treatment Effect of Antithrombotic Regimens on Bleeding or Ischemic Events

- The treatment effect of apixaban vs VKA on bleeding and death or ischemic events by HAS-BLED and CHA2DS2-VASc scores.
- There was no treatment effect interaction by baseline bleeding or stroke risk for the comparison of apixaban vs VKA (P for trend = 0.14)

J Am Coll Cardiol 2022;79:417-427

← Apixaban Better VKA Better →

Event/Risk Score	KM% at 6 Mor Aspirin	nths [Events] Placebo	HR (95% CI) Aspirin vs Placebo	
ISTH Major or CRNM Bleeding	3			
HAS-BLED				
0 (N = 2)		0.0 [0]		
1 (N = 258)	16.9 [21]	4.9 [6]	3.67 (1.48-9.10)	
2 (N = 1,195)	14.7 [81]	9.2 [53]	1.66 (1.18-2.34)	-=-
3 (N = 1,975)	17.4 [161]	10.2 [90]	1.80 (1.39-2.32)	+
4 (N = 761)	19.8 [67]	9.9 [34]	2.21 (1.47-3.32)	
5 (N = 169)	16.1 [11]	18.1 [13]	0.80 (0.36-1.79)	
6 (N = 24)	0.0 [0]	0.0 [0]		
7 (N = 2)	0.0 [0]	0.0 [0]		
Death or Ischemic Events				
CHA2DS2-VASc				
1 (N = 168)	1.2 [1]	2.5 [2]		
2 (N = 635)	3.5 [11]	3.6 [11]	1.02 (0.44-2.36)	— —
3 (N = 997)	5.0 [24]	6.4 [32]	0.80 (0.47-1.35)	
4 (N = 1,083)	6.3 [33]	7.7 [40]	0.81 (0.51-1.29)	
5 (N = 805)	6.8 [24]	7.6 [31]	0.82 (0.48-1.40)	
6 (N = 428)	11.5 [26]	9.1 [18]	1.32 (0.73-2.39)	
7 (N = 197)	8.6 [8]	13.4 [13]	0.61 (0.26-1.46)	
8 (N = 63)	13.7 [4]	12.9 [4]	1.08 (0.27-4.30)	
9 (N = 10)	0.0 [0]	20.0 [1]		
				0.25 1 4

← Aspirin Better Placebo Better →

Treatment Effect Of Antithrombotic Regimens on Bleeding or Ischemic Events


- The treatment effect of aspirin vs placebo on bleeding and death or ischemic events by HAS-BLED and CHA2DS2-VASc scores.
- There was no treatment effect interaction by baseline bleeding or stroke risk for the comparison of placebo vs aspirin (*P* for trend = 0.47).

Treatment Effect of Antithrombotic Regimens on Death or Ischemic Events

	Number (Rate) of Apixaban	Events at 6 Mo VKA	onths HR	(95% CI)	Interaction P Value
Stroke					
≤2	0 (0.0%)	0 (0.0%)			
≥3	13 (0.8%)	25 (1.4%)	0.52 (0.27-1.02)		
Death or ischemic events					0.737
≤2	12 (3.0%)	13 (3.4%)	0.85 (0.39-1.87)		
≥3	127 (7.4%)	131 (7.4%)	0.98 (0.77-1.25)	H=H	
Death or hospitalization					0.531
≤2	80 (19.7%)	81 (21.5%)	0.92 (0.67-1.25)	⊢ •−	
≥3	435 (25.0%)	513 (29.2%)	0.82 (0.73-0.94)	1-1	

В

А



- The treatment effect of (A) apixaban vs VKA and (B) aspirin vs placebo on stroke, death or ischemic events, and death or hospitalization by CHA₂DS₂-VASc category.
- There was no treatment effect interaction by baseline stroke risk for the comparison of apixaban vs VKA (p for trend = 0.84) or placebo vs aspirin (*P* for trend = 0.80).

J Am Coll Cardiol 2022;79:417–427

Summary of the main findings

AUGUSTUS A Randomized 2x2 Factorial Trial							
4,386 patients with receiving a P2Y ₁₂ in (with documented r	hibitor	Apixaban 5 mg twice/day	VKA dose adjusted INR of 2.0-3.0	Aspirin 81 mg once/day	Placebo once/day		
Major or clinically relevant nonmajor bleeding	HAS-BLED ≤2	8.8%	14.4%	15.1%	8.4%		
		HR: 0.57		HR: 1.86			
	HAS-BLED ≥3	12.1%	16.3%	17.8%	10.4%		
		HR:	HR: 0.72		HR: 1.81		
	CHA ₂ DS ₂ -VASc ≤2	19.7%	21.5%	21.7%	19.5%		
Death or hospitalization		HR: 0.92		HR: 1.09			
nospitatization	CHA ₂ DS ₂ -VASc ≥3	25.0%	29.2%	27.8%	26.4%		
		HR:	HR: 0.82		HR: 1.07		

No significant interactions were found on treatment effect of apixaban versus VKA or aspirin versus placebo across CHA₂DS₂-VASc or HAS-BLED risk categories.

Harskamp, R.E. et al. J Am Coll Cardiol. 2022;79(5):417-427.

Limitations

- AUGUSTUS trial was not powered to detect interactions between study medications and outcomes according to HAS-BLED or CHA₂DS₂-VASc subgroups.
 - This should be particularly emphasized for ischemic events, including stroke.
- AUGUSTUS trial had a numerically lower TTR for patients who received VKA compared with other RCT of stroke prevention.
- P2Y₁₂ inhibitor choice was open-label and at investigator discretion, and clinicians could theoretically have used higher-potency P2Y₁₂ inhibitors in patients at lower risk of bleeding, introducing confounding by indication.
 - Clopidogrel was used in >90% of patients irrespective of bleeding risk.
- AUGUSTUS randomized patients a median of 6 days (maximum of 14 days) after the qualifying ACS or PCI event, and these findings may not apply to patients very shortly after an ACS or PCI event.

Conclusions

- An antithrombotic regimen including apixaban is associated with less bleeding and hospitalization compared with a regimen with VKA or aspirin, independent of HAS-BLED and CHA₂DS₂-VASc scores.
- These findings support the use of apixaban (and possibly other DOACs) and a P2Y₁₂ inhibitor without aspirin for most patients with AF and ACS and/or undergoing PCI, regardless of baseline bleeding and stroke risk.